On April 24, the FDA awarded three Commissioner's National Priority Vouchers to psychedelic programs. Two went to organizations that are not publicly traded in the US: the Usona Institute (a nonprofit developing psilocybin for major depressive disorder) and Transcend Therapeutics (whose methylone program is being acquired by Otsuka). The third went to Compass Pathways (CMPS), the only publicly traded company in the group and the most advanced classic psychedelic program in the world. For investors watching this sector, Compass is the one that matters right now.
The CNPV compresses the FDA's review of a new drug application from the standard ten to twelve months down to one to two months. That is a meaningful acceleration. When Eli Lilly received the same voucher for its oral GLP-1 drug Foundayo, the company went from NDA submission to approval in fifty days. That decision came on April 1, 2026, just weeks before the psychedelic vouchers were issued.
But the voucher only works once Compass files. And Compass cannot file until its rolling NDA is complete.
Compass reported positive data from both of its Phase 3 trials this year. COMP005, a single-dose study in 258 participants across 32 US sites, hit its primary endpoint in mid-2025. COMP006, a larger two-dose study with 568 participants across North America and Europe, did the same in February 2026. The FDA has since granted rolling submission, meaning Compass can send completed sections of the application as they are ready rather than packaging the whole thing at once. But additional safety and durability data are still coming in. The target window for completing the submission is Q4 2026, between October and December. Until then, the voucher sits on the shelf.
The math is simple. If Compass completes its filing by late Q4 and the CNPV delivers a review in line with the Lilly precedent, an approval decision could come in early 2027. That is fast by historical standards, but still at least six months from where we sit today.
The stock moves tell this story clearly. Before the executive order on April 18, Compass Pathways was trading around $6.66. On the Monday after the order, it surged 42% to $9.46. As of early May it is holding near $9, meaning the market sees the CNPV as real and durable value for the company closest to filing. Compass is the direct beneficiary and the stock is acting like it.
“The voucher only works once Compass files. And Compass cannot file until its rolling NDA is complete.”
The rest of the sector barely moved or gave it back. AtaiBeckley (ATAI) jumped 22% from $4.03 to $4.90 on the day of the order, then drifted back to roughly $4.14. Definium Therapeutics (DFTX) rose only about 5% over two days, from $22.68 to $23.84, then gave back the entire gain and now trades around $21.72, slightly below where it started. Helus Pharma (HELP), which was also dealing with a CEO change the same week, saw a similarly muted reaction and now trades around $5.35.
The pattern is the same in each case. The policy news arrived, the market looked at where each company actually stands in the clinic, and moved on.
And that is the key point. A Compass approval would validate the regulatory path for every program behind it, from Definium's lysergide in anxiety and depression, to Helus Pharma's deuterated psilocin in MDD, to AtaiBeckley's intranasal mebufotenin in treatment-resistant depression. All three have Breakthrough Therapy designations of their own, but none of them are filing this year. Definium has three Phase 3 readouts expected in 2026. Helus is running its Phase 3 PARADIGM program. AtaiBeckley is initiating Phase 3 for BPL-003 this quarter. These are real milestones, but they are clinical milestones, not regulatory ones.
The market priced in the policy tailwind. It priced in the voucher. Now it needs the next concrete event, and that event is Compass completing its NDA. Until then, the sector is in wait state.
Three things to watch between now and a potential approval. First, the pace of Compass's rolling submission. Each module that goes to the FDA brings the filing date closer. Second, the additional safety and durability data still being collected, which will round out the NDA package. Third, the Phase 3 readouts from Definium, Helus, and AtaiBeckley. Positive data from any of those programs would reinforce the broader case that this class of drugs works. Negative data would do the opposite.
The voucher shortened the runway. It did not eliminate the wait.